Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

45 results
Display

Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib

Kang D, Han Z, Oh GH, Joo Y, Choi HJ, Song JJ

PURPOSE: Sorafenib, a multikinase inhibitor, is the standard therapy for patients with advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the treatment, therefore, we tried to unravel the underlying mechanism...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function

Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK

BACKGROUND/AIMS: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

Kim DY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells

Chang H, Sung JH, Moon SU, Kim HS, Kim JW, Lee JS

PURPOSE: Rearrangement of the proto-oncogene rearranged during transfection (RET) has been newly identified potential driver mutation in lung adenocarcinoma. Clinically available tyrosine kinase inhibitors (TKIs) target RET kinase activity, which...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea

Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W

Multiple therapeutic modalities are available for hepatocellular carcinoma (HCC) treatment. We aimed to evaluate the trends for HCC treatment in Korea. Recent trends and patterns in treatment modalities were assessed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis

Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH

BACKGROUND/AIMS: Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial. We compared the outcomes of hepatic resection (HR), transarterial chemoembolization (TACE), and sorafenib therapy as treatments for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy

Park JG

BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma

Seo MS, Kim JK, Shim JY

We report a case of regression of multiple pulmonary metastases, which originated from hepatocellular carcinoma after treatment with intravenous administration of high-dose vitamin C. A 74-year-old woman presented to the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm

Hwang S, Lee J, Lee JM, Hong SH, Lee MA, Chun HG, Chun HJ, Lee SH, Jung ES

The occurrence of hepatocellular carcinoma (HCC) is closely associated with viral hepatitis or alcoholic hepatitis. Although active surveillance is ongoing in Korea, advanced or metastatic HCC is found at initial...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis

Woo HY, Heo J

Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sorafenib in the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Report of Four Cases

Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W

With an increasing number of patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT), tumor recurrence remains the main limiting factor for long-term survival. Although sorafenib is available for advanced...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient

Kim JO, Jun DW, Tae HJ, Lee KN, Lee HL, Lee OY, Choi HS, Yoon BC, Hahm JS

Tumor lysis syndrome is rare in hepatocellular carcinoma (HCC), but it has been reported more frequently recently in response to treatments such as transcatheter arterial chemoembolization (TACE), radiofrequency thermal ablation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH

BACKGROUND/AIMS: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib

Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, Lall C

Hepatocellular carcinomas are highly vascular tumors, showing progressive hypervascularity by the process of neoangiogenesis. Tumor angiogenesis is critical for tumor growth as well as metastatic spread therefore, imaging and quantification...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Newer treatments for advanced hepatocellular carcinoma

Song MJ, Bae SH

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The only curative treatment modalities for HCC are surgery, percutaneous ablation, and liver transplantation. Unfortunately, the majority of patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Liver Abscess in Advanced Hepatocellular Carcinoma after Sorafenib Treatment

Shin SK, Jung YK, Yoon HH, Kwon OS, Kim YS, Choi DJ, Kim JH

Hepatocellular carcinoma (HCC) is a critical global health issue and the third most common cause of cancer-related deaths worldwide. The majority of patients who present HCC are already at an...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent advances in systemic chemotherapy of hepatocellular carcinoma

Kim BH, Park JW

Sorafenib, as the first approved molecularly targeted agent for hepatocellular carcinoma (HCC), has changed the treatment paradigm for patients with advanced HCC. Although a significant survival advantage has been achieved...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis

Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH

  • KMID: 1712330
  • Gut Liver.
  • 2013 Nov;7(6):696-703.
BACKGROUND/AIMS: We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. METHODS: In total, 143 consecutive patients with unresectable...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diagnosis and Treatment of Gastrointestinal Stromal Tumor

Kang YK, Koo DH

  • KMID: 2267783
  • Korean J Med.
  • 2013 Oct;85(4):341-353.
Gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors of the gastrointestinal tract, have represented an important advance in oncology field with the success of molecular targeted therapy....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction

Oh D, Park HC, Lim HY, Yoo BC

Sorafenib is a multi-targeted kinase inhibitor, which is the current standard treatment for advanced hepatocellular carcinoma (HCC). Only one case of radiation recall dermatitis (RRD) associated with sorafenib has been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr